Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of Bruton’s tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies. It was designed to minimize off-target inhibition of TEC- and EGFR-family kinases. Zanubrutinib is more se...
Na minha lista:
| Principais autores: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2023-03-01
|
| Serier: | Frontiers in Oncology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1130595/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|